Table 1

 Demographics of patients with pyoderma gangrenosum (PG) entered into the study

Infliximab group (n = 13)Placebo group (n = 17)
*Median (range).
IBD, inflammatory bowel disease; DLQI, dermatology life quality index.
Age (y)50 (20–80)55 (33–81)
Sex (M:F)6:77:10
IBD7/1312/17
    Crohn’s disease5/78/12
    Ulcerative colitis2/74/12
Duration of PG (weeks)*26 (2–676)12 (2–288)
Site of PG
    Limbs78
    Peristomal46
    Perineum23
DLQI score98
EuroQol score1212
Concomitant medication
    Minocycline10
    Prednisolone75
    Methotrexate02
    Tacrolimus paste11
    Topical steroid12